GlassScriptPhysician profile
Lauren D Conner
NPI 1689851370
$1,569.70
in general payments reported to CMS, 2019-2025
15 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $112 · 2023: $214 · 2024: $501 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.90 | 2021-2025 | |
| Janssen Biotech, INC. | $254.42 | 2024-2025 | Tremfya |
| Genzyme Corporation | $193.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $173.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.63 | 2021-2024 | Farxiga |
| Ucb, INC. | $77.52 | 2024 | Bimzelx |
| Lilly USA, LLC | $70.02 | 2022-2025 | Ebglyss, Taltz |
| Glaxosmithkline, LLC. | $41.13 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $32.38 | 2021 | |
| Amgen INC. | $29.09 | 2023-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $24.70 | 2021 | |
| Incyte Corporation | $23.08 | 2025 | Opzelura |
| Almatica Pharma LLC | $15.93 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.23 | 2025 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.